Hybridoma technology for the production of monoclonal antibodies

Abstract

Given the size and scope of the global pharmaceutical market, monoclonal antibodies (mAbs) have a promising future in a broad range of areas such as autoimmune diseases, infectious diseases, and cancer therapies. A decisive medical treatment is achievable since mAbs only identify their target antigens and not additional irrelevant proteins. As global demand grows, hybridoma technology, which enables the production of specific mAbs for target antigens, is gaining even more importance. Since the invention of the cell fusion technique known as 'hybridoma technology' to continuously produce targeted mAbs in vitro, their generation has become more widespread. The crucial point is the use of cancer cells. Antibody-producing B lymphocytes can become immortal through somatic fusion with myeloma cells, with the resulting hybridoma cells retaining not only the innate functions of antibody-producing B lymphocytes but also the malignant capacity for infinite proliferation in vitro. This review includes general information regarding hybridoma technology and hybridoma-based mAb generation.

Cite this article as: Sait A, Korkmaz S, Parmaksız A, Erbaş O. Hybridoma technology for the production of monoclonal antibodies. D J Med Sci 2022;8(3):141-149.

Data Sharing Statement:
The data that support the findings of this study are available from the corresponding author upon reasonable request.

Idea /concept, design, data collection, control: A.S. S.K. A.P.; Literture review, writing the article, critical review: A.S.; Critical review: O.E.

The authors declared no conflicts of interest with respect to the authorship and/ or publication of this article.

The authors received no financial support for the research and/or authorship of this article.